Searching for improved mimetic peptides inhibitors preventing conformational transition of amyloid-β42 monomer

A series of novel mimetic peptides were designed, synthesised and biologically evaluated as inhibitors of A beta(42) aggregation. One of the synthesised peptidic compounds, termed compound 7 modulated A beta(42) aggregation as demonstrated by thioflavin T fluorescence, acting also as an inhibitor of the cytotoxicity exerted by A beta(42) aggregates. The early stage interaction between compound 7 and the A beta(42) monomer was investigated by replica exchange molecular dynamics (REMD) simulations and docking studies. Our theoretical results revealed that compound 7 can elongate the helical conformation state of an early stage A beta(42) monomer and it helps preventing the formation of beta-sheet structures by interacting with key residues in the central hydrophobic cluster (CHC). This strategy where early on-pathway events are monitored by small molecules will help the development of new therapeutic strategies for Alzheimer's disease.